ESRRG · Western blot design guide

ESRRG Western Blot Planning Guide

Plan an ESRRG Western blot around the catalog-observed 51.3 kDa band, image-backed A01470-1 evidence, HPA controls, and verified protocol records.

Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
Western blot protocol sheet for ESRRG (ESRRG): expected band 51.3 kDa, antibody A01470-1, and guide-derived SDS-PAGE protocol steps
ESRRG Western blot protocol sheet — expected band 51.3 kDa, antibody A01470-1, controls and PMC citations. Open the full ESRRG WB guide →

ESRRG Western Blot Experimental Design Guide

Expected bands, documented protocol parameters, controls and antibodies — the at-a-glance facts below, then the full design guide.

Must know before running
Expected band 51.3 kDa
Observed band Not reported — verify product WB image
Gel 12-15%
Positive control ⓘ Stomach
Negative control ⓘ Adipose tissue
Important caveats
Reasons your observed band may differ from the expected size.
ⓘ Calculated mass 51.3 kDa
ⓘ Localization Nucleus
ⓘ Processing / PTM Record-dependent
ⓘ Reactivity Human / Mouse / Rat
Section 1

Real Curated ESRRG Western Blot Protocols

Start with the molecular-weight rule, then compare verified publication-derived conditions.

Recommended Western blot protocol parameters
Sample / lysateStomach
Gel %12-15%
Load20-30 µg total protein per lane
TransferSemi-dry, standard transfer
Membrane0.45 µm PVDF
Blocking5% non-fat milk or 5% BSA in TBST
PrimaryA01470-1 at datasheet starting dilution
Primary incubationOvernight at 4 °C with gentle agitation
SecondarySpecies-matched HRP conjugate at validated dilution
Wash3 × 5 min in TBST
DetectionChemiluminescent substrate
ExposureBracket exposures to avoid saturation
Section 2

What Is the Expected ESRRG Western Blot Band Size?

Use the product-observed 51.3 kDa band as the primary planning value and retain the UniProt calculated mass as context.

What am I looking at on my blot?
51.3 kDaMatches the authoritative product WB observation.
51.3 kDa calculatedUse as UniProt context, not as a replacement observed band.
Unexpected additional signalDo not assign identity without orthogonal positive/negative controls.
💡Expected ESRRG appearancePlan around 51.3 kDa and keep the calculated mass as supporting context.
How each factor affects band size
Catalog-observed band51.3 kDa; use this as the primary experimental expectation.
Calculated mass51.3 kDa from UniProt P62508; retain as context.
Gel selection12-15%; shared with the recommended protocol and poster.
Specificity checkCompare the lead HPA positive and negative controls with A01470-1.
Why is my band missing or off?
SituationLikely causeNext action
51.3 kDaMatches the authoritative product WB observation.Confirm with orthogonal controls and the linked product record.
Additional bandMay reflect processing, modification, or non-specific signal.Run a dilution series and compare positive/negative controls.
Weak signalTarget abundance or transfer may be limiting.Verify transfer, increase positive-control abundance, and bracket exposure.

Sample controls for ESRRG Western blot

🧪Use Stomach as the first positive-control candidate and Adipose tissue as the HPA Not detected negative candidate.
Positive control: Stomach (High)
Negative control: Adipose tissue (Not detected)
HPA protein score determines control status; other expression data is supporting context only.

HPA tissue expression evidence for ESRRG

Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.

Positive expression · recommended positive controls

TissueCell typeLevelEvidenceSource
Stomach Reported tissue cells High Protein (HPA) HPA →
Kidney Reported tissue cells Medium Protein (HPA) HPA →
Cerebellum Reported tissue cells Low Protein (HPA) HPA →
Breast Reported tissue cells Low Protein (HPA) HPA →

Undetected expression · recommended negative controls

TissueCell typeLevelEvidenceSource
Adipose tissue Reported tissue cells Not detected Protein (HPA) HPA →
Appendix Reported tissue cells Not detected Protein (HPA) HPA →
Section 3

Advanced ESRRG Western Blot Tips

Deeper troubleshooting and optimisation questions for ESRRG, answered from its protein features.

Which band should guide the blot?
Use 51.3 kDa, the observation attached to the authoritative A01470-1 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 51.3 kDa expectation.
Which positive control should I start with?
Start with Stomach, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Adipose tissue as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 12-15% consistently across the quick facts, protocol table, and poster.
What transfer method to use for ESRRG Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should A01470-1 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
No verified publication protocol was supplied; use only the deterministic recommended protocol.
Boster reagents

ESRRG Western Blot Reagents

Human/Mouse/Rat-reactive ESRRG Western blot reagents with authoritative product imagery.

Real WB data Western blot validation image for ESRRG using A01470-1; observed band 51.3 kDa
Anti-strogen Related Receptor gamma/ESRRG Antibody Picoband®
Cat # A01470-1

Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.

Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.

References

  1. UniProt P62508
  2. Human Protein Atlas — ESRRG
  3. A01470-1 product record
  4. PMC4520632 — MiR-940 inhibits hepatocellular carcinoma growth and correlates with prognosis of hepatocellular carcinoma patients (Cancer science, 2015)
  5. PMC10485992 — ESRRG-PKM2 axis reprograms metabolism to suppress esophageal squamous carcinoma progression and enhance anti-PD-1 therapy efficacy (Journal of translational medicine, 2023)
  6. PMC9476228 — Placental expression of estrogen-related receptor gamma is reduced in fetal growth restriction pregnancies and is mediated by hypoxia† (Biology of reproduction, 2022)